{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:31:06Z","timestamp":1782894666110,"version":"3.54.5"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005742","name":"Universidade Federal De Goi\u00e1s","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005742","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Cyclin-dependent kinase (CDK) 4\/6 inhibitors have significantly advanced the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer, improving outcomes. However, their concurrent use with statins, a widely prescribed class of drugs, may pose a risk of rhabdomyolysis due to pharmacokinetic and pharmacodynamic interactions. This systematic review analyzes reported cases to characterize clinical presentations, therapeutic approaches, and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed, Embase, Scopus, and Web of Science from inception to January 2026 for case reports and case series documenting rhabdomyolysis in patients treated with CDK4\/6 inhibitors. Data on demographics, clinical features, laboratory findings, management strategies, and outcomes were extracted. Quality assessment of the included cases was performed using the Joanna Briggs Institute Critical Appraisal Checklist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven case reports involving female patients aged 55\u201381 years were analyzed. All patients were treated for metastatic breast cancer with CDK4\/6 inhibitors (ribociclib, palbociclib, or abemaciclib) alongside statins (simvastatin, atorvastatin, or rosuvastatin). Rhabdomyolysis onset ranged from 3 days to 48 months after initiation of combination therapy, or shortly after statin dose escalation in the setting of long-term CDK4\/6 inhibitor use. Clinical presentations included severe myalgia, muscle weakness, and dark urine, with creatine kinase levels ranging from 3,070 to 47,000 U\/L. Acute kidney injury was reported in five cases. Management primarily involved cessation of the implicated drugs and aggressive hydration, with adjunctive treatments such as corticosteroids, plasma exchange, or intravenous immunoglobulin. Five patients recovered fully, one had partial recovery with persistent renal dysfunction, and one fatality was reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rhabdomyolysis due to CDK4\/6 inhibitor\u2013statin interactions is a rare but potentially life-threatening complication. Vigilant monitoring, timely intervention, and tailored treatment strategies are essential for preventing complications and improving patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00280-026-04913-w","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:14:49Z","timestamp":1782879289000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CDK4\/6 inhibitor\u2013statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4518-2090","authenticated-orcid":false,"given":"Rafael Batista","family":"Jo\u00e3o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9448-6114","authenticated-orcid":false,"given":"Leonardo Ribeiro","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo C\u00e9sar","family":"Ragazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4145-8598","authenticated-orcid":false,"given":"Ruffo","family":"Freitas-Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"4913_CR1","doi-asserted-by":"publisher","first-page":"204209862211250","DOI":"10.1177\/20420986221125006","volume":"13","author":"S Lucas","year":"2022","unstructured":"Lucas S, Ailani J, Smith TR, Abdrabboh A, Xue F, Navetta MS (2022) Pharmacovigilance: reporting requirements throughout a product\u2019s lifecycle. Ther Adv Drug Saf 13:20420986221125006","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"4913_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison L, Loibl S, Turner NC (2024) The CDK4\/6 inhibitor revolution: a game-changing era for breast cancer treatment. Nat Rev Clin Oncol 21(2):89\u2013105","journal-title":"Nat Rev Clin Oncol"},{"key":"4913_CR3","doi-asserted-by":"publisher","first-page":"175883592311872","DOI":"10.1177\/17588359231187201","volume":"15","author":"M Pegram","year":"2023","unstructured":"Pegram M, Pietras R, Dang CT, Murthy R, Bachelot T, Janni W et al (2023) Evolving perspectives on the treatment of HR+\/HER2\u2009+\u2009metastatic breast cancer. Ther Adv Med Oncol 15:17588359231187201","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"4913_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13058-015-0661-5","volume":"18","author":"RS Finn","year":"2016","unstructured":"Finn RS, Aleshin A, Slamon DJ (2016) Targeting the cyclin-dependent kinases (CDK) 4\/6 in estrogen receptor-positive breast cancers. Breast Cancer Res 18(1):17","journal-title":"Breast Cancer Res"},{"issue":"17","key":"4913_CR5","doi-asserted-by":"publisher","first-page":"6350","DOI":"10.3390\/ijms21176350","volume":"21","author":"R Roncato","year":"2020","unstructured":"Roncato R, Angelini J, Pani A, Cecchin E, Sartore-Bianchi A, Siena S et al (2020) CDK4\/6 inhibitors in breast cancer treatment: potential interactions with drug, gene, and pathophysiological conditions. Int J Mol Sci 21(17):6350","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4913_CR6","first-page":"631","volume":"32","author":"S Ramkumar","year":"2016","unstructured":"Ramkumar S, Raghunath A, Raghunath S (2016) Statin therapy: review of safety and potential side effects. Acta Cardiol Sin 32(6):631\u2013639","journal-title":"Acta Cardiol Sin"},{"key":"4913_CR7","doi-asserted-by":"publisher","first-page":"175883591983386","DOI":"10.1177\/1758835919833867","volume":"11","author":"M Bellet","year":"2019","unstructured":"Bellet M, Ahmad F, Villanueva R, Valdivia C, Palomino-Doza J, Ruiz A et al (2019) Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Ther Adv Med Oncol 11:1758835919833867","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"4913_CR8","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3390\/pharmaceutics12090856","volume":"12","author":"DA Garrison","year":"2020","unstructured":"Garrison DA, Talebi Z, Eisenmann ED, Sparreboom A, Baker SD (2020) Role of OATP1B1 and OATP1B3 in drug\u2013drug interactions mediated by tyrosine kinase inhibitors. Pharmaceutics 12(9):856","journal-title":"Pharmaceutics"},{"issue":"2","key":"4913_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1248\/bpb.b14-00767","volume":"38","author":"K Maeda","year":"2015","unstructured":"Maeda K (2015) Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs. Biol Pharm Bull 38(2):155\u2013168","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"4913_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ekir.2022.09.026","volume":"8","author":"JF Hebert","year":"2023","unstructured":"Hebert JF, Burfeind KG, Malinoski D, Hutchens MP (2023) Molecular mechanisms of rhabdomyolysis-induced kidney injury: from bench to bedside. Kidney Int Rep 8(1):17\u201329","journal-title":"Kidney Int Rep"},{"key":"4913_CR11","volume-title":"Cochrane handbook for systematic reviews of interventions","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J et al (eds) (2019) Cochrane handbook for systematic reviews of interventions, 2nd edn. Wiley, Chichester (UK)","edition":"2"},{"key":"4913_CR12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol 134:178\u2013189","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"4913_CR13","first-page":"MR000026","volume":"2011","author":"T Horsley","year":"2011","unstructured":"Horsley T, Dingwall O, Sampson M (2011) Checking reference lists to find additional studies for systematic reviews. Cochrane Database Syst Rev 2011(8):MR000026","journal-title":"Cochrane Database Syst Rev"},{"key":"4913_CR14","doi-asserted-by":"crossref","unstructured":"Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R et al (2020) Systematic reviews of etiology and risk. In: Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z (eds) JBI Manual for Evidence Synthesis. JBI. Available from: https:\/\/jbi-global.atlassian.net\/wiki\/spaces\/MANUAL\/pages\/355598596\/7.+Systematic+reviews+of+etiology+and+risk","DOI":"10.46658\/JBIRM-17-06"},{"key":"4913_CR15","first-page":"47","volume":"15","author":"O Badran","year":"2023","unstructured":"Badran O, Abu Amna M, Turgeman I, Bar-Sela G (2023) Rhabdomyolysis induced by the interaction between ribociclib and statins: case report and literature review. Breast Cancer (Dove Med Press) 15:47\u201350","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"9","key":"4913_CR16","doi-asserted-by":"publisher","first-page":"e255632","DOI":"10.1136\/bcr-2023-255632","volume":"16","author":"SW Teo","year":"2023","unstructured":"Teo SW, Hayes T, Gome J (2023) Ribociclib may potentiate rosuvastatin effect in causing late onset rhabdomyolysis. BMJ Case Rep 16(9):e255632","journal-title":"BMJ Case Rep"},{"key":"4913_CR17","doi-asserted-by":"publisher","first-page":"1026434","DOI":"10.3389\/fonc.2022.1026434","volume":"12","author":"F Poumeaud","year":"2022","unstructured":"Poumeaud F, Fontanier A, Dion J, Mathevet Q, Cointault O, Uro-Coste E et al (2022) Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: a case report. Front Oncol 12:1026434","journal-title":"Front Oncol"},{"issue":"3","key":"4913_CR18","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/1078155220945365","volume":"27","author":"C Streicher","year":"2021","unstructured":"Streicher C, Daulange A, Madranges N, Vayre L (2021) Severe rhabdomyolysis induced by possible drug\u2013drug interaction between ribociclib and simvastatin. J Oncol Pharm Pract 27(3):722\u2013726","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"4913_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12883-019-1490-4","volume":"19","author":"V Nersesjan","year":"2019","unstructured":"Nersesjan V, Hansen K, Krag T, Duno M, Jeppesen TD (2019) Palbociclib in combination with simvastatin induces severe rhabdomyolysis: a case report. BMC Neurol 19(1):247","journal-title":"BMC Neurol"},{"key":"4913_CR20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fonc.2017.00150","volume":"7","author":"KL Nelson","year":"2017","unstructured":"Nelson KL, Stenehjem D, Driscoll M, Gilcrease GW (2017) Fatal statin-induced rhabdomyolysis by possible interaction with palbociclib. Front Oncol 7:150","journal-title":"Front Oncol"},{"issue":"1","key":"4913_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s10549-025-07845-w","volume":"215","author":"TH Kim","year":"2025","unstructured":"Kim TH, Zobi A, Teplinsky E (2025) Collateral damage: rhabdomyolysis from concurrent abemaciclib and rosuvastatin use. Breast Cancer Res Treat 215(1):6","journal-title":"Breast Cancer Res Treat"},{"key":"4913_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/978-981-10-1844-2_9","volume-title":"Cancer and chronic conditions: addressing the problem of multimorbidity in cancer patients and survivors","author":"JP Turner","year":"2016","unstructured":"Turner JP, McKinnon RA, Bell JS (2016) The management of polypharmacy in people with cancer and chronic conditions. In: Koczwara B (ed) Cancer and chronic conditions: addressing the problem of multimorbidity in cancer patients and survivors. Springer, Singapore, pp 261\u2013286"},{"issue":"5","key":"4913_CR23","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1200\/JOP.2016.018317","volume":"13","author":"GS Calip","year":"2017","unstructured":"Calip GS, Xing S, Jun DH, Lee WJ, Hoskins KF, Ko NY (2017) Polypharmacy and adherence to adjuvant endocrine therapy for breast cancer. J Oncol Pract 13(5):e451\u2013e462","journal-title":"J Oncol Pract"},{"issue":"11","key":"4913_CR24","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.cmet.2022.09.023","volume":"34","author":"M Martin-Perez","year":"2022","unstructured":"Martin-Perez M, Urdiroz-Urricelqui U, Bigas C, Benitah SA (2022) The role of lipids in cancer progression and metastasis. Cell Metab 34(11):1675\u20131699","journal-title":"Cell Metab"},{"issue":"12","key":"4913_CR25","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1001\/jamaoncol.2016.0429","volume":"2","author":"R Haque","year":"2016","unstructured":"Haque R, Shi J, Schottinger JE, Chung J, Avila C, Amundsen B et al (2016) Cardiovascular disease after aromatase inhibitor use. JAMA Oncol 2(12):1590\u20131597","journal-title":"JAMA Oncol"},{"issue":"1","key":"4913_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-020-05749-5","volume":"183","author":"S Harborg","year":"2020","unstructured":"Harborg S, Heide-Jorgensen U, Ahern TP, Ewertz M, Cronin-Fenton D, Borgquist S (2020) Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study. Breast Cancer Res Treat 183(1):153\u2013160","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"4913_CR27","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK et al (2015) Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur Heart J 36(17):1012\u20131022","journal-title":"Eur Heart J"},{"issue":"3","key":"4913_CR28","doi-asserted-by":"publisher","first-page":"omx104","DOI":"10.1093\/omcr\/omx104","volume":"2018","author":"S Ezad","year":"2018","unstructured":"Ezad S, Cheema H, Collins N (2018) Statin-induced rhabdomyolysis: a complication of a commonly overlooked drug interaction. Oxf Med Case Rep 2018(3):omx104","journal-title":"Oxf Med Case Rep"},{"issue":"1","key":"4913_CR29","first-page":"58","volume":"15","author":"PA Torres","year":"2015","unstructured":"Torres PA, Helmstetter JA, Kaye AM, Kaye AD (2015) Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J 15(1):58\u201369","journal-title":"Ochsner J"},{"issue":"5","key":"4913_CR30","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s11883-003-0008-z","volume":"5","author":"U Laufs","year":"2003","unstructured":"Laufs U, Liao JK (2003) Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep 5(5):372\u2013378","journal-title":"Curr Atheroscler Rep"},{"issue":"8","key":"4913_CR31","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2165\/00002018-200528080-00002","volume":"28","author":"IP Hargreaves","year":"2005","unstructured":"Hargreaves IP, Duncan AJ, Heales SJ, Land JM (2005) The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical\/clinical implications. Drug Saf 28(8):659\u2013676","journal-title":"Drug Saf"},{"issue":"5","key":"4913_CR32","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/jcsm.12579","volume":"11","author":"A Sahebkar","year":"2020","unstructured":"Sahebkar A, Cicero AFG, Di Giosia P, Pomilio I, Stamerra CA, Giorgini P et al (2020) Pathophysiological mechanisms of statin-associated myopathies: possible role of the ubiquitin-proteasome system. J Cachexia Sarcopenia Muscle 11(5):1177\u20131186","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"7","key":"4913_CR33","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s40264-024-01413-9","volume":"47","author":"G Bell","year":"2024","unstructured":"Bell G, Thoma A, Hargreaves IP, Lightfoot AP (2024) The role of mitochondria in statin-induced myopathy. Drug Saf 47(7):643\u2013653","journal-title":"Drug Saf"},{"key":"4913_CR34","first-page":"59","volume":"13","author":"CA Calderon-Ospina","year":"2020","unstructured":"Calderon-Ospina CA, Hernandez-Somerson M, Garcia AM, Mejia A, Tamayo-Agudelo C, Laissue P et al (2020) A pharmacogenomic dissection of a rosuvastatin-induced rhabdomyolysis case evokes the polygenic nature of adverse drug reactions. Pharmgenomics Pers Med 13:59\u201370","journal-title":"Pharmgenomics Pers Med"},{"issue":"8","key":"4913_CR35","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"E Link","year":"2008","unstructured":"SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S et al (2008) SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study. N Engl J Med 359(8):789\u2013799","journal-title":"N Engl J Med"},{"issue":"21","key":"4913_CR36","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","volume":"134","author":"BS Wiggins","year":"2016","unstructured":"Wiggins BS, Saseen JJ, Page RL 2nd, Reed BN, Sneed K, Kostis JB et al (2016) Recommendations for management of clinically significant drug\u2013drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation 134(21):e468\u2013e495","journal-title":"Circulation"},{"key":"4913_CR37","doi-asserted-by":"publisher","first-page":"102956","DOI":"10.1016\/j.ctrv.2025.102956","volume":"137","author":"TK Sahin","year":"2025","unstructured":"Sahin TK, Kavgaci G, Guven DC, Aksoy S (2025) Drug-drug interactions and special considerations in breast cancer patients treated with CDK4\/6 inhibitors: a comprehensive review. Cancer Treat Rev 137:102956","journal-title":"Cancer Treat Rev"},{"key":"4913_CR38","unstructured":"Pfizer Labs (2025) IBRANCE\u00ae (palbociclib) tablets, for oral use. US prescribing information"},{"key":"4913_CR39","unstructured":"European Medicines Agency (2025) Kisqali, INN-ribociclib: product information"},{"key":"4913_CR40","unstructured":"Eli Lilly and Company (2025) VERZENIO\u00ae (abemaciclib) tablets, for oral use. US prescribing information"},{"key":"4913_CR41","volume-title":"The use of the WHO-UMC system for standardized case causality assessment","author":"World Health Organization","year":"2002","unstructured":"World Health Organization (2002) The use of the WHO-UMC system for standardized case causality assessment. Uppsala Monitoring Centre, Uppsala"},{"issue":"2","key":"4913_CR42","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239\u2013245","journal-title":"Clin Pharmacol Ther"},{"issue":"32","key":"4913_CR43","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1093\/eurheartj\/ehac360","volume":"43","author":"G Liuzzo","year":"2022","unstructured":"Liuzzo G, Patrono C (2022) The absolute cardiovascular benefits of PCSK9 inhibitors and ezetimibe added to maximally tolerated statin therapy depend on individual baseline cardiovascular risk. Eur Heart J 43(32):3016\u20133017","journal-title":"Eur Heart J"},{"key":"4913_CR44","doi-asserted-by":"publisher","first-page":"e069116","DOI":"10.1136\/bmj-2021-069116","volume":"377","author":"SU Khan","year":"2022","unstructured":"Khan SU, Yedlapati SH, Lone AN, Hao Q, Guyatt G, Delvaux N et al (2022) PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis. BMJ 377:e069116","journal-title":"BMJ"},{"issue":"3","key":"4913_CR45","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10549-023-07218-1","volume":"204","author":"E Joyce","year":"2024","unstructured":"Joyce E, Tao X, Stearns V, Hayes DF, Storniolo AM, Kidwell KM et al (2024) Polypharmacy, over-the-counter medications, and aromatase inhibitor adherence in early-stage breast cancer. Breast Cancer Res Treat 204(3):539\u2013546","journal-title":"Breast Cancer Res Treat"},{"key":"4913_CR46","doi-asserted-by":"publisher","first-page":"e943492","DOI":"10.12659\/AJCR.943492","volume":"25","author":"R Huff","year":"2024","unstructured":"Huff R, Karpinska-Leydier K, Maddineni G, Begosh-Mayne D (2024) Rhabdomyolysis risk: the dangers of Tribulus terrestris, an over-the-counter supplement. Am J Case Rep 25:e943492","journal-title":"Am J Case Rep"},{"issue":"2","key":"4913_CR47","first-page":"30","volume":"13","author":"TM Bush","year":"2007","unstructured":"Bush TM, Rayburn KS, Holloway SW, Sanchez-Yamamoto DS, Allen BL, Lam T et al (2007) Adverse interactions between herbal and dietary substances and prescription medications: a clinical survey. Altern Ther Health Med 13(2):30\u201335","journal-title":"Altern Ther Health Med"},{"issue":"3","key":"4913_CR48","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/jcpt.12805","volume":"44","author":"JCM Chan","year":"2019","unstructured":"Chan JCM, Ng MH, Wong RSM, Tomlinson B (2019) A case of simvastatin-induced myopathy with SLCO1B1 genetic predisposition and co-ingestion of linagliptin and Stevia rebaudiana. J Clin Pharm Ther 44(3):381\u2013383","journal-title":"J Clin Pharm Ther"},{"issue":"13","key":"4913_CR49","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1200\/JCO.2014.58.7550","volume":"33","author":"G Nightingale","year":"2015","unstructured":"Nightingale G, Hajjar E, Swartz K, Andrel-Sendecki J, Chapman A (2015) Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol 33(13):1453\u20131459","journal-title":"J Clin Oncol"},{"issue":"1","key":"4913_CR50","doi-asserted-by":"publisher","first-page":"113275","DOI":"10.1016\/j.yexcr.2022.113275","volume":"420","author":"D Mademtzoglou","year":"2022","unstructured":"Mademtzoglou D, Relaix F (2022) From cyclins to CDKIs: cell cycle regulation of skeletal muscle stem cell quiescence and activation. Exp Cell Res 420(1):113275","journal-title":"Exp Cell Res"},{"issue":"4","key":"4913_CR51","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3892\/ol.2024.14278","volume":"27","author":"M Teomete","year":"2024","unstructured":"Teomete M, Cabuk D, Korkmaz T, Seber S, Ozturk OF, Aver B et al (2024) Recommendations for cyclin-dependent kinase 4\/6 inhibitor treatments in the context of co-morbidity and drug interactions (review). Oncol Lett 27(4):145","journal-title":"Oncol Lett"},{"issue":"20","key":"4913_CR52","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925\u20131936","journal-title":"N Engl J Med"},{"issue":"3","key":"4913_CR53","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/cc13897","volume":"18","author":"N Petejova","year":"2014","unstructured":"Petejova N, Martinek A (2014) Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review. Crit Care 18(3):224","journal-title":"Crit Care"},{"issue":"3","key":"4913_CR54","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ekir.2021.11.033","volume":"7","author":"S Gupta","year":"2022","unstructured":"Gupta S, Caza T, Herrmann SM, Sakhiya VC, Jhaveri KD (2022) Clinicopathologic features of acute kidney injury associated with CDK4\/6 inhibitors. Kidney Int Rep 7(3):618\u2013623","journal-title":"Kidney Int Rep"},{"issue":"6","key":"4913_CR55","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s11912-024-01540-7","volume":"26","author":"T Magge","year":"2024","unstructured":"Magge T, Rajendran S, Brufsky AM, Foldi J (2024) CDK4\/6 inhibitors: the devil is in the detail. Curr Oncol Rep 26(6):665\u2013678","journal-title":"Curr Oncol Rep"},{"key":"4913_CR56","doi-asserted-by":"publisher","first-page":"101519","DOI":"10.1016\/j.gore.2024.101519","volume":"56","author":"N Ibrahim","year":"2024","unstructured":"Ibrahim N, Altman AD (2024) Docetaxel-induced myositis in the treatment of uterine leiomyosarcoma: a case report and review of literature. Gynecol Oncol Rep 56:101519","journal-title":"Gynecol Oncol Rep"},{"issue":"1","key":"4913_CR57","first-page":"75","volume":"25","author":"A Sulkes","year":"2023","unstructured":"Sulkes A, Reinhorn D, Cohen T, Peysakhovich T, Neiman V, Brenner B (2023) Docetaxel-induced acute myositis. Isr Med Assoc J 25(1):75\u201376","journal-title":"Isr Med Assoc J"},{"issue":"1","key":"4913_CR58","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/ijd.12437","volume":"55","author":"RR Winkelmann","year":"2016","unstructured":"Winkelmann RR, Yiannias JA, DiCaudo DJ, Trotter SC, Farhey Y, Griffing WL et al (2016) Paclitaxel-induced diffuse cutaneous sclerosis: a case with associated esophageal dysmotility, Raynaud\u2019s phenomenon, and myositis. Int J Dermatol 55(1):97\u2013100","journal-title":"Int J Dermatol"},{"issue":"3","key":"4913_CR59","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3390\/biomedicines11030905","volume":"11","author":"MB Pedrosa","year":"2023","unstructured":"Pedrosa MB, Barbosa S, Vitorino R, Ferreira R, Moreira-Gon\u00e7alves D, Santos LL (2023) Chemotherapy-induced molecular changes in skeletal muscle. Biomedicines 11(3):905","journal-title":"Biomedicines"},{"issue":"2","key":"4913_CR60","first-page":"96","volume":"1785","author":"BT McGrogan","year":"2008","unstructured":"McGrogan BT, Gilmartin B, Carney DN, McCann A (2008) Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 1785(2):96\u2013132","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"4913_CR61","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s12012-024-09941-7","volume":"25","author":"C Pal","year":"2025","unstructured":"Pal C (2025) Small molecules targeting mitochondria: a mechanistic approach to combating doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol 25(2):216\u2013247","journal-title":"Cardiovasc Toxicol"},{"key":"4913_CR62","doi-asserted-by":"publisher","first-page":"670862","DOI":"10.3389\/fphar.2021.670862","volume":"12","author":"L Molenaar-Kuijsten","year":"2021","unstructured":"Molenaar-Kuijsten L, Van Balen DEM, Beijnen JH, Steeghs N, Huitema ADR (2021) A review of CYP3A drug\u2013drug interaction studies: practical guidelines for patients using targeted oral anticancer drugs. Front Pharmacol 12:670862","journal-title":"Front Pharmacol"},{"issue":"2","key":"4913_CR63","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12281-020-00386-3","volume":"14","author":"C Gustafson","year":"2020","unstructured":"Gustafson C, Koslosky M, Leslie J, Walczak C (2020) Antifungal and oral anticancer therapy drug interactions. Curr Fungal Infect Rep 14(2):130\u2013140","journal-title":"Curr Fungal Infect Rep"},{"key":"4913_CR64","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.2147\/DDDT.S86983","volume":"9","author":"A Kotlinska-Lemieszek","year":"2015","unstructured":"Kotlinska-Lemieszek A, Klepstad P, Haugen DF (2015) Clinically significant drug\u2013drug interactions involving opioid analgesics used for pain treatment in patients with cancer: a systematic review. Drug Des Devel Ther 9:5255\u20135267","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"4913_CR65","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1093\/oncolo\/oyae094","volume":"29","author":"M Aapro","year":"2024","unstructured":"Aapro M, Fogli S, Morlion B, Danesi R (2024) Opioid metabolism and drug\u2013drug interaction in cancer. Oncologist 29(11):931\u2013942","journal-title":"Oncologist"},{"key":"4913_CR66","first-page":"79","volume":"12","author":"KM Venkatesh","year":"2021","unstructured":"Venkatesh KM, Acharya S, Holla R (2021) Assessment of potential drug-drug interaction among the patients receiving cancer chemotherapy: a cross-sectional study. J Pharmacol Pharmacother 12:79\u201385","journal-title":"J Pharmacol Pharmacother"},{"issue":"1","key":"4913_CR67","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0009-9236(03)00066-3","volume":"74","author":"JB McCrea","year":"2003","unstructured":"McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL et al (2003) Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 74(1):17\u201324","journal-title":"Clin Pharmacol Ther"},{"issue":"22","key":"4913_CR68","doi-asserted-by":"publisher","first-page":"7120","DOI":"10.3390\/jcm12227120","volume":"12","author":"V Bourdin","year":"2023","unstructured":"Bourdin V, Bigot W, Vanjak A, Burlacu R, Lopes A, Champion K et al (2023) Drug\u2013drug interactions involving dexamethasone in clinical practice: myth or reality? J Clin Med 12(22):7120","journal-title":"J Clin Med"},{"key":"4913_CR69","doi-asserted-by":"publisher","first-page":"808848","DOI":"10.3389\/fphar.2022.808848","volume":"13","author":"H Wang","year":"2022","unstructured":"Wang H, Shi H, Wang Y, Wang N, Li Y, Yang Q et al (2022) Potentially hazardous drug\u2013drug interactions associated with oral antineoplastic agents prescribed in Chinese tertiary care teaching hospital settings: a multicenter cross-sectional study. Front Pharmacol 13:808848","journal-title":"Front Pharmacol"},{"issue":"1","key":"4913_CR70","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14740338.2024.2387323","volume":"24","author":"Y Peng","year":"2025","unstructured":"Peng Y, Zhou Y, Zhou X, Jia X, Zhong Y (2025) A disproportionality analysis of CDK4\/6 inhibitors in the FDA Adverse Event Reporting System (FAERS). Expert Opin Drug Saf 24(1):25\u201333","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"4913_CR71","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40360-024-00770-6","volume":"25","author":"W Lin","year":"2024","unstructured":"Lin W, Zeng Y, Weng L, Yang J, Zhuang W (2024) Comparative analysis of adverse events associated with CDK4\/6 inhibitors based on FDA\u2019s adverse event reporting system: a case-control pharmacovigilance study. BMC Pharmacol Toxicol 25(1):47","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"4913_CR72","doi-asserted-by":"publisher","first-page":"104096","DOI":"10.1016\/j.esmoop.2024.104096","volume":"10","author":"E Agostinetto","year":"2025","unstructured":"Agostinetto E, Pfeiler G, Hlauschek D, Mayer EL, Lambertini M, de Azambuja E et al (2025) Drug\u2013drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS. ESMO Open 10(1):104096","journal-title":"ESMO Open"},{"issue":"18","key":"4913_CR73","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738\u20131748","journal-title":"N Engl J Med"},{"issue":"7","key":"4913_CR74","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N et al (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 19(7):904\u2013915","journal-title":"Lancet Oncol"},{"issue":"24","key":"4913_CR75","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA et al (2018) Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36(24):2465\u20132472","journal-title":"J Clin Oncol"},{"issue":"1","key":"4913_CR76","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO et al (2015) The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25\u201335","journal-title":"Lancet Oncol"},{"issue":"3","key":"4913_CR77","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H et al (2015) Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373(3):209\u2013219","journal-title":"N Engl J Med"},{"issue":"4","key":"4913_CR78","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.japh.2022.02.014","volume":"62","author":"S Amin","year":"2022","unstructured":"Amin S, McKeirnan KC (2022) The physician perspective on pharmacist\u2013physician collaboration and trust. J Am Pharm Assoc (2003) 62(4):1304\u20131312","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"12","key":"4913_CR79","doi-asserted-by":"publisher","first-page":"e1917094","DOI":"10.1001\/jamanetworkopen.2019.17094","volume":"2","author":"L Moja","year":"2019","unstructured":"Moja L, Polo Friz H, Capobussi M, Kwag K, Banzi R, Ruggiero F et al (2019) Effectiveness of a hospital-based computerized decision support system on clinician recommendations and patient outcomes: a randomized clinical trial. JAMA Netw Open 2(12):e1917094","journal-title":"JAMA Netw Open"},{"issue":"1","key":"4913_CR80","doi-asserted-by":"publisher","first-page":"e100683","DOI":"10.1136\/bmjhci-2022-100683","volume":"30","author":"LG Armando","year":"2023","unstructured":"Armando LG, Miglio G, de Cosmo P, Cena C (2023) Clinical decision support systems to improve drug prescription and therapy optimisation in clinical practice: a scoping review. BMJ Health Care Inf 30(1):e100683","journal-title":"BMJ Health Care Inf"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04913-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04913-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04913-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:29:44Z","timestamp":1782887384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04913-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4913"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04913-w","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This review used published data only.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare the following potential conflicts of interest. Rafael Batista Jo\u00e3o: Has served as a guest speaker for the company Libbs. Leonardo Ribeiro Soares: Has received honoraria for advisory roles from MSD and BD; has received research funding from Daiichi Sankyo and BD. Paulo C\u00e9sar Ragazzo: Has received honoraria for advisory and guest speaker roles from Ach\u00e9, UCB, and Union Chimique Belge; travel\/accommodation\/expenses from Ach\u00e9. Ruffo Freitas-Junior: Has received honoraria for advisory roles from Novartis, Pfizer, MSD, and AstraZeneca; research grants (to institution) from Libbs; and travel\/accommodation\/expenses from AstraZeneca.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statement"}}],"article-number":"67"}}